Simplex Trading’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-13,900
| Closed | -$31K | – | 10031 |
|
|
2024
Q4 | $31K | Sell |
13,900
-10,100
| -42% | -$52.7K | ﹤0.01% | 6338 |
|
|
2024
Q3 | $68K | Buy |
24,000
+11,600
| +94% | +$35.9K | ﹤0.01% | 5608 |
|
|
2024
Q2 | $36K | Sell |
12,400
-2,400
| -16% | -$6.56K | ﹤0.01% | 6396 |
|
|
2024
Q1 | $47K | Buy |
+14,800
| New | +$49.3K | ﹤0.01% | 6322 |
|
|
2023
Q4 | – | Sell |
-5,200
| Closed | -$12K | – | 10077 |
|
|
2023
Q3 | $12K | Buy |
5,200
+2,900
| +126% | +$6.08K | ﹤0.01% | 7077 |
|
|
2023
Q2 | $4K | Sell |
2,300
-7,700
| -77% | -$19.7K | ﹤0.01% | 8134 |
|
|
2023
Q1 | $30K | Buy |
10,000
+3,000
| +43% | +$18K | ﹤0.01% | 6503 |
|
|
2022
Q4 | $37K | Buy |
7,000
+6,000
| +600% | +$27.4K | ﹤0.01% | 6235 |
|
|
2022
Q3 | $3K | Buy |
1,000
+200
| +25% | +$661 | ﹤0.01% | 9173 |
|
|
2022
Q2 | $2K | Buy |
800
+100
| +14% | +$278 | ﹤0.01% | 9459 |
|
|
2022
Q1 | $3K | Sell |
700
-2,900
| -81% | -$13.1K | ﹤0.01% | 9764 |
|
|
2021
Q4 | $24K | Buy |
3,600
+2,500
| +227% | +$17K | ﹤0.01% | 8174 |
|
|
2021
Q3 | $10K | Hold |
1,100
| – | – | ﹤0.01% | 8955 |
|
|
2021
Q2 | $11K | Buy |
1,100
+1,088
| +9,067% | +$9.74K | ﹤0.01% | 9062 |
|
|
2021
Q1 | $11K | Buy |
12
+10
| +500% | +$98 | ﹤0.01% | 7857 |
|
|
2020
Q4 | $2K | Buy |
+2
| New | +$21 | ﹤0.01% | 8028 |
|
Other funds holding PSTX
Simplex Trading's PSTX Position: Q1 2025 in Review
Simplex Trading sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 14,032 shares — an estimated $134K sold.
Simplex Trading first reported a position in PSTX in Q4 2020 and held it in 9 quarters. The position peaked at $134K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Simplex Trading reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Simplex Trading sold 14,032 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $134K.
- Simplex Trading first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
- Simplex Trading's Poseida Therapeutics, Inc. Common Stock position peaked at $134K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Simplex Trading's 13F filing for Q1 2025, filed 12 May 2025.